AR-420626 (AR 420626; AR420626) is a novel and potent allosteric agonist of FFA3 (GPR41) receptor (pEC50 value of 5.74) with the potential for the treatment of neurogenic diarrheal disorders by suppressing nAChR-mediated neural pathways.
Physicochemical Properties
| Molecular Formula | C21H18CL2N2O3 |
| Molecular Weight | 417.285223484039 |
| Exact Mass | 416.069 |
| Elemental Analysis | C, 60.45; H, 4.35; Cl, 16.99; N, 6.71; O, 11.50 |
| CAS # | 1798310-55-0 |
| PubChem CID | 91885415 |
| Appearance | Off-white to light yellow solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 619.3±55.0 °C at 760 mmHg |
| Flash Point | 328.3±31.5 °C |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.653 |
| LogP | 3.71 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 28 |
| Complexity | 733 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | ClC1C=CC(=CC=1NC(C1=C(C)NC2CCCC(C=2C1C1=CC=CO1)=O)=O)Cl |
| InChi Key | GGTYQECCGLBHGS-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C21H18Cl2N2O3/c1-11-18(21(27)25-15-10-12(22)7-8-13(15)23)20(17-6-3-9-28-17)19-14(24-11)4-2-5-16(19)26/h3,6-10,20,24H,2,4-5H2,1H3,(H,25,27) |
| Chemical Name | N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide |
| Synonyms | AR 420626; AR-420626; AR420626 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon. Neurogastroenterol Motil. 2018 Jan;30(1):10.1111/nmo.13157. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~20 mg/mL (~47.9 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (4.79 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3964 mL | 11.9821 mL | 23.9641 mL | |
| 5 mM | 0.4793 mL | 2.3964 mL | 4.7928 mL | |
| 10 mM | 0.2396 mL | 1.1982 mL | 2.3964 mL |